抗發炎治療藥與市場:標的、技術、市場、策略、預測

已開發國家的平均壽命延長，隨著人口高齡化，慢性疼痛及急性疼痛的發生率關聯的罹患率增加，對患者與其家族來說作為QOL問題的疼痛管理變得更受到重視。

本報告提供抗發炎治療藥的市場調查，發炎性疾病概要，治療標的，法律制度，市場影響因素的分析，市場規模的變化、預測，市場佔有率，參與企業的簡介等資料。

目錄

摘要整理

發炎途徑

發炎途徑標的連鎖

細胞激素

• 白細胞介素6(IL-6)
• 白細胞介素IL-6R
• 白細胞介素-21(IL-21)
• 白細胞介素-21R(IL-21R)
• 白細胞介素-23(IL-23)
• 白細胞介素-23R(IL-23R)
• 白細胞介素-17A(IL-17A)
• 白細胞介素-17C(IL-17C)
• 白細胞介素17A/17F
• 白細胞介素-17RA(IL-17RA)
• 白細胞介素17
• 白細胞介素-22(IL-22)

Janus激酶/蛋白酪氨酸激酶抑制劑

訊號傳達蛋白質

• 轉印的訊號轉換器&活化劑

轉化生長因子-βRI/RII(TGF-βRI/RII)

視黃酸相關孤兒受體RORyt

市場的狀況

市場規模

競爭情形

免疫介質市場評估

• 支援可能市場
• 競爭情形

市場參與企業的簡介

Mediating the Inflammatory Cascade

The influence of immune mediators on inflammatory diseases has put the immune mediated therapeutics at the center of inflammatory disease treatment and management. The result is a growing list of approved and development-stage drugs designed to inhibit at least one of the fifteen pathway targets that drive the transcription and secretion of inflammatory cytokines into the extracellular space where they impact patient morbidity and inflammatory disease burden. The competitive landscape now includes more than two dozen drug developers. As this marketspace has evolved, the prime product opportunities, which we define as the drugability of individual pathway targets factored by the inverse of the number of competing drugs and late-stage candidates, has been shrinking. The distribution of therapeutic products in this segment varies across pathway elements, with 84 percent targeting signaling proteins and ligands, and receptors and transcription factors accounting for 8 percent each.

Targeting Key Inflammatory Pathways:

The identification of key immune mechanisms as causative for human inflammatory disease has led to the approval and rapid development of novel therapeutic agents.

Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development.

Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

• What are the immune factors that are responsible for immune mediated inflammatory Diseases?

• What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets?

• What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?

• What is the size of the market today, who are the market share leaders?

• What will be the effects of competing pathway solutions for the same indication and how will this dynamic impact revenue forecasts over the next four years?

• What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics?

Table of Contents

Executive Summary

Inflammatory Pathways

Inflammatory Pathway Cascade Targets

Cytokines

• Interleukin 6 (IL-6)
• Interleukin IL-6R

• Interleukin-21 (IL-21)
• Interleukin-21R (IL-21R)
• Interleukin-23 (IL-23)

• Interleukin-23R (IL-23R)
• Interleukin-17A (IL-17A)
• Interleukin-17C (IL-17C)

• Interleukin 17A/17F
• Interleukin-17RA (IL-17RA)
• Interleukin 17
• Interleukin-22 (IL-22)

Janus Kinase/Tyrosine Kinase Inhibitors

Signaling Proteins

• Signal Transducer & Activator of Transcription

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)

Retinoic acid-related orphan receptor RORyt

Market Status

Market Size

Competitive Landscape

Immune Mediated Market Assessment

• Addressable Market
• Competitive Landscape

Profiles of Market Participants